FDA Drug recall D-0639-2022
Olanzapine Tablets, USP 10 mg, 30-count bottles, Rx only, Manufactured for: Macleods Pharma USA , Inc
- FDA Drug
- Class II
- terminated
- Published 2022-03-09
On 2022-03-09 the FDA classified a Class II recall of Olanzapine Tablets, USP 10 mg, 30-count bottles, Rx only, Manufactured for: Macleods Pharma USA , Inc by Macleods Pharma Usa, citing cGmp Deviations.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0639-2022 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2022-02-16 |
| Published | 2022-03-09 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Macleods Pharma Usa |
| Distribution | US |
Product
Olanzapine Tablets, USP 10 mg, 30-count bottles, Rx only, Manufactured for: Macleods Pharma USA , Inc. Plainsboro, NJ 08536, Manufactured by: Macleods Pharmaceuticals Ltd., Baddi, HImachal Pradesh, India, NDC 33342-070-07.
Reason
cGmp Deviations
Identifiers
| ndc | 33342-067-07 |
|---|---|
| ndc | 33342-067-44 |
| ndc | 33342-067-12 |
| ndc | 33342-067-11 |
| ndc | 33342-068-07 |
| ndc | 33342-068-44 |
| ndc | 33342-068-12 |
| ndc | 33342-068-11 |
| ndc | 33342-069-07 |
| ndc | 33342-069-44 |
| ndc | 33342-069-12 |
| ndc | 33342-069-11 |
| ndc | 33342-070-07 |
| ndc | 33342-070-15 |
| ndc | 33342-070-12 |
| ndc | 33342-070-44 |
| ndc | 33342-070-11 |
| ndc | 33342-071-07 |
| ndc | 33342-071-15 |
| ndc | 33342-071-12 |
| ndc | 33342-071-44 |
| ndc | 33342-071-11 |
| ndc | 33342-072-07 |
| ndc | 33342-072-15 |
| ndc | 33342-072-12 |
| ndc | 33342-072-44 |
| ndc | 33342-072-11 |
| code_info | Lot #: BOB42029A, BOB4202B, Exp. Date 09/2022 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0639-2022%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.